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Abstract
Dengue type-2 virus infection in mice induces a subpopulation of T lymphocytes to produce a cytokine cytotoxic factor, which induces
macrophages (MP) to produce a biologically active cytotoxic cytokine, the MP cytotoxin (CF2). Previously we have identified the presence
of intermediate-affinity receptors for CF2 on mouse peritoneal MP. The present study was undertaken to identify the CF2-receptors
(CF2-R) on murine T cells followed by their purification and characterization. Receptor binding assay and Scatchard analysis revealed
single, high-affinity (1.0309 nM) receptors for CF2 on T cells (22 000 receptors per cell). The binding of [125I]CF2 on murine T cells was
saturable and specific. Furthermore, CF2-R was purified from normal mouse T cell plasma membrane by affinity chromatography
followed by reversed-phase high-pressure liquid chromatography. The presence of CF2-R was confirmed by indirect dot-blot assay and its
binding with [125I]CF2. The purified CF2-R is a 90^95-kDa protein as characterized by sodium dodecyl sulfate^polyacrylamide gel
electrophoresis and immunoblot analysis. The chemical crosslinking of [125I]CF2 and its receptor complex showed a product of 100^110
kDa on different subpopulations of murine T cells. The pretreatment of target cells with anti-CF2-R antisera inhibited the cytotoxic
activity of CF2 in a dose-dependent manner and thus confirmed the biological significance of CF2-R. Moreover, the presence of CF2-R
was also identified on normal human peripheral blood mononuclear cells and T and B cells by crosslinking with [125I]CF2, thus revealing
the possible role of CF2 and CF2-R in the immunopathogenesis of dengue virus disease.
: 2003 Federation of European Microbiological Societies. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Dengue virus type-2 (DV-2) infection in mice produces
immunosuppression characterized by spleen atrophy, re-
duced numbers of T lymphocytes, depressed humoral
and cell-mediated immune responses to heterologous and
homologous antigens, and depressed macrophage (MP)
functions [1^3]. These features are caused by the develop-
ment of an antigen speci¢c suppressor pathway and a non-
speci¢c cytotoxic pathway in the spleen of DV-2-infected
mice. Antigen speci¢c immunosuppression is induced by
the DV-2 speci¢c suppressor cascade consisting of three
generations of suppressor T cells and their soluble prod-
ucts (reviewed in [4]). Antigen non-speci¢c immunosup-
pression observed in DV-2-infected mice is mediated by
a mouse cytotoxic factor (mCF) produced by splenic
T lymphocytes (Thy 1.2+, Lyt 1+233) [1,2]. On native
polyacrylamide gel electrophoresis (PAGE), mCF is a
highly potent protein molecule of 45 kDa. It dissociates
into two equally active heterodimer chains of 20 and
25 kDa on sodium dodecyl sulfate (SDS)^PAGE and
has an isoelectric point of 6.5 [5]. The 19-amino acid
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N-terminal sequence of mCF has no homology to other
known cytokines, T cell proteases, and other cytotoxic
proteins [5]. The mouse cytotoxic factor kills mainly
H-2A (a mouse major histocompatibility complex) nega-
tive MP, T lymphocytes, and lymphoid cells of several
species [2,3].
DV-2 speci¢c mCF induces H-2A positive splenic and
peritoneal MP to produce another cytotoxin, CF2 [3]. CF2
is also produced in vivo in DV-2-infected mice as well as
mice inoculated with mCF [6]. CF2 enhances the cytotoxic
e¡ect of mCF, and mCF and CF2 cause antigen non-spe-
ci¢c immunosuppression in mice [3,5]. CF2 is a heat- and
pH-labile, biologically active, cytotoxic protein with a mo-
lecular mass of 10^12 kDa. The ¢rst 10-amino acid se-
quence of CF2 from the C-terminus has no homology to
the other known cytotoxic proteins and cytokines (unpub-
lished data). CF2 kills H-2A negative and positive MP,
CD4þ and CD8þ T cells, and mast cells in 1 h by inducing
Ca2þ in£ux into the target cells [7]. Cytotoxicity of CF2 is
dependent on the Ca2þ and production of nitric oxide and
superoxide ions in vitro and in vivo [7^9]. Also mCF and
CF2 both produce various other immunopathological le-
sions in mice including increased capillary permeability
and damage to the blood^brain barrier by release of his-
tamine [10,11]. In addition, in vitro treatment of human
blood leukocytes with mCF/CF2 decreases the E-rosetting
capacity of T cells and alters the functions of monocytes
[12,13]. Human dengue hemorrhagic fever/shock syndrome
(DHF) is characterized by increased vascular permeability,
thrombocytopenia, alterations in blood leukocytes, and
cerebral edema [14]. It would thus appear that mCF and
CF2 are both capable of reproducing the pathological le-
sions of DHF in mice, and mCF and CF2 are both patho-
genesis-related proteins, at least in mouse dengue infec-
tion.
To further understand the mechanism of CF2 biol-
ogy, we extended our studies to identify its cellular re-
ceptor on target cells. Cytokines act on cells in an auto-
crine and paracrine fashion through their receptor binding
sites; CF2 kills CD4þ and CD8þ T cells and H-2A neg-
ative MP in paracrine fashion and kills H-2A positive
MP in autocrine fashion [12]. CF2 gets adsorbed onto
the plasma membrane of the target cells, and the cytotoxic
activity of CF2 is inhibited by plasma membrane-stabi-
lizing drugs [6,12]. The putative receptor binding sites
for CF2 are neuraminidase-sensitive, suggesting that sialic
acid residues are crucial for the formation of a recep-
tor site for CF2 [12]. We have previously identi¢ed the
presence of intermediate-a⁄nity type of receptors on
mouse MP, and the binding of [125I]CF2 to MP was satu-
rable and reversible, and dependent on temperature, pH
and time [15]. The present study was undertaken to inves-
tigate the presence of a CF2-receptor (CF2-R) on mouse
T cells, to purify and characterize it, and to identify the
biologically active role of CF2-R in CF2-induced cytotox-
icity.
2. Materials and methods
2.1. Animals
Inbred Swiss albino mice, aged 3^4 months, were ob-
tained from the colony maintained in our department and
used in experiments according to the guidelines of the
animal facility of the institute.
2.2. Virus
DV-2 strain P23085 was obtained from the National
Institute of Virology, Pune, India, and had undergone
brain-to-brain passages in young mice. The virus strain
produced 100% mortality after intracerebral (i.c.) inocula-
tion in infant and adult mice. The infected mouse brain
was ground in a chilled mortar and pestle with 3.6 ml of
chilled Hank’s balanced salt solution. The ground suspen-
sion was centrifuged at 3000Ug for 10 min at 4‡C, and the
supernatant was aliquoted and stored at 370‡C for fur-
ther use. The virus was used in doses of 1000 LD50 in all
experiments [16]. The virus titers were determined by i.c.
inoculation in adult mice and LD50 calculation by the
method of Reed and Muench [17]. Normal mouse brain
suspension was prepared similarly for control groups.
2.3. Cell preparations
Five ml of heparinized Eagle’s minimum essential me-
dium (MEM) containing 10% fetal calf serum (FCS) was
inoculated by intraperitoneal (i.p.) injection into adult
mice, and peritoneal lavages were aspirated into a 9-cm
glass Petri dish. After incubation at 37‡C for 2 h in the
presence of 5% CO2, the viability of glass adherent cells
was assayed by exclusion of trypan blue dye. The purity of
MP was screened by their phagocytic activity of neutral
red dye as described previously [13] and was 93^96% in
di¡erent preparations. For T and B cells, a single cell
suspension of the spleen cells was prepared in a 9-cm glass
Petri dish. The glass non-adherent cells were poured into a
MEM-treated nylon wool column for 1 h at 37‡C to ob-
tain enriched T and B cell populations [18,19]. The viabil-
ity of cells was calculated using trypan blue dye, and the
purity of cell preparations was assayed as described pre-
viously [20] and was 93^95% in di¡erent preparations.
CD4þ and CD8þ cells were obtained by treatment of en-
riched T cells with CD8 and CD4 monoclonal antibody
(Dako, Glostrup, Denmark), respectively. Human periph-
eral blood mononuclear cells and T and B cells were ob-
tained as previously described [20].
2.4. Preparation and puri¢cation of CF
The CF was prepared from the spleens of DV-2-infected
mice and puri¢ed by low-pressure liquid chromatography
using a Sephacryl S-200 column as described earlier [5].
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2.5. Preparation and puri¢cation of CF2
CF2 was prepared by the technique described previously
[3]. Brie£y, normal mouse MP were treated with 5 Wg of
CF at 4‡C for 1 h in the presence of 5% CO2. The cell
sheet was washed and further incubated at 37‡C for 24 h
in the presence of normal saline. The adherent cells were
scrapped o¡, sonicated, centrifuged at 3000Ug, and the
collected supernatant was assayed for cytotoxic activity
[3,6]. The crude CF2 so prepared was puri¢ed with high-
pressure liquid chromatography (HPLC; LKB-Pharmacia,
Uppsala, Sweden) [11].
2.6. Cytotoxicity assay for CF/CF2
Normal mouse spleen cells were used as target cells to
assay cytotoxic activity of CF/CF2 [1,3]. Brie£y, the target
cells (1U106) and the test solution (CF or CF2) were
mixed in equal volume in a 96-well U-well persplex plate
(Nunc, Denmark) and incubated at 4‡C for 1 h. Viable
nucleated cells were counted using trypan blue dye, and
the percentage of non-viable cells was calculated. The data
were corrected by deducting background non-viable cells.
2.7. Radiolabeling of CF2
CF2 was radiolabeled with 125I (Bhabha Atomic Re-
search Center, Mumbai, India) by the lactoperoxidase
method [21] with some modi¢cations. CF2 (500 Wg) was
added to 0.5 mCi 125I in the presence of 2 Wg of lactoper-
oxidase. The reaction was accelerated by addition of 0.88
mM H2O2 in four aliquots of 5 Wl each and terminated by
addition of 25 Wl of lactoperoxidase stop bu¡er [phos-
phate-bu¡ered saline (PBS), pH 7.0, saturated with tyro-
sine (10 mg ml31), 10% glycerol, 0.1% xylene cyanol]. The
free iodine was separated from [125I]CF2 by using a Se-
phacryl S-200 column as previously described [15].
2.8. Binding assay and Scatchard analysis
Puri¢ed mouse splenic T cells (1U106) were suspended
in 1 ml MEM containing 10% FCS (pH 7.2). Various
concentrations of [125I]CF2 (5 pM to 15 nM) were added
to the cells in the presence or absence of a 100-fold excess
of unlabeled CF2 to assess speci¢c binding, with a ¢nal
inoculation volume of 1 ml in cryotubes (Nunc, Den-
mark). Radioactivity of the cells was counted in a gamma
counter (LKB-Pharmacia). Non-speci¢c binding, deter-
mined in the presence of a 100-fold excess of unlabeled
CF2, was subtracted from the total binding to give speci¢c
binding. Data from the binding experiments were sub-
jected to Scatchard analysis [22]. For inhibition studies,
[125I]CF2 (12 nM) was preincubated with anti-CF2 anti-
sera or heterologous DV-2 speci¢c anti-suppressor factor
(SF) antisera for 1 h at 37‡C prior to binding.
2.9. Preparation of puri¢ed plasma membrane from
T lymphocytes
Membrane preparation was performed as described pre-
viously [23^25] with some modi¢cations. The normal
mouse T cells (6^8U108 ml31) were puri¢ed as described
above and washed twice with PBS and sedimented at
600Ug for 10 min. The pellet was dissolved with an equal
volume of PBS supplemented with 2 mM phenyl methyl
sulfonyl £uoride, 1 mM pepstatin, 1 mM leupeptin and
2 mM O-phenanthroline. The cells were lysed by sonica-
tion, and the disrupted cell suspension was centrifuged at
2000Ug for 10 min. The supernatant was centrifuged at
20 000Ug for 1.5 h to obtain the crude plasma membrane
pellet, which was then dissolved in PBS containing pro-
tease inhibitors and 1% Triton X-100. The solution was
magnetic-stirred for 30 min at 4‡C and then centrifuged at
105 000Ug for 1.5 h (Sorvall S-28, Asheville, NC, USA).
The resultant supernatant was collected and used as puri-
¢ed T cell plasma membrane.
2.10. Puri¢cation of CF2-R by
a⁄nity chromatography
HPLC-puri¢ed CF2 (20 Wg) was dissolved in the cou-
pling bu¡er (0.1 M sodium bicarbonate, 0.5 M NaCl, pH
8.3) and coupled to cyanogen bromide (CNBr)-activated
Sepharose 4B according to the manufacturer’s suggestions.
Approximately 80% of the CF2 were coupled to the gel,
and after washing, the puri¢ed T cell plasma membrane
preparation was adsorbed onto the CF2-coupled CNBr-
activated beads for 1 h at 37‡C. The column was washed
with 50 mM Tris^HCl (pH 8.0) to remove the unbound
membrane protein. The receptor was then eluted with
0.2 M glycine^HCl (pH 2.5), and the pH was adjusted
with 0.2 M Tris^HCl (pH 9.2) to pH 7.2. Protein concen-
trations of eluted fractions were determined using bovine
serum albumin (BSA) as a standard [26].
2.11. Dot-blot assay
The nitrocellulose dot-blot assay was performed to iden-
tify the presence of CF2-R protein puri¢ed from the CF2-
a⁄nity column. Di¡erent fractions of receptor protein
were applied to the nitrocellulose membrane in a dot-
blot apparatus (Millipore, Bedford, MA, USA). The mem-
brane was blocked with 3% BSA in 10 mM Tris^HCl (pH
7.4) overnight. The blots were washed with PBS^T
(Tween-20, 0.05%) and treated with 5 Wg of CF2 for 1 h
at 37‡C. The blots were washed and incubated with anti-
CF2 antisera at room temperature followed by horserad-
ish peroxidase conjugate anti-mouse IgG (Sigma, St.
Louis, MO, USA) and developed with a substrate contain-
ing diaminobenzidine (Sigma) and hydrogen peroxide (Sig-
ma).
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2.12. Puri¢cation of CF2-R by HPLC
The a⁄nity-puri¢ed CF2-R was further puri¢ed by a
Shoedex protein column (KW-803, Millipore) using re-
versed-phase (RP)-HPLC. The column was preequili-
brated with 0.5 M Tris^HCl (pH 7.4). The di¡erent frac-
tions of receptor protein were ¢rst dissolved in 0.5 M Tris^
HCl (pH 7.4), and 100 Wl of sample was loaded into the
injection loop. The protein was eluted with the same sol-
vent, and chromatographic elution was monitored by ab-
sorbance at 280 nm. In some experiments, the CF2-R was
treated with 5 mM of dithiothreitol (DTT, Sigma). The
puri¢ed protein peak was collected in Eppendorf tubes,
and the protein content was estimated.
2.13. Preparation of antisera
Antisera against CF2-R were raised in mice by injecting
5 Wg of puri¢ed CF2-R emulsi¢ed in Freund’s complete
adjuvant (Sigma) i.p. at day 0, followed by a booster dose
of 5 Wg CF2-R in Freund’s incomplete adjuvant (Sigma)
i.p. 15 days later. Blood was collected on day 30, and the
separated antisera were pooled and stored at 320‡C. A
similar protocol was used to prepare anti-CF2 antisera
and anti-SF and anti-SF-receptor (SF-R) antisera [27].
2.14. SDS^PAGE and immunoblotting
The HPLC-puri¢ed CF2-R was run on a 12% SDS^
PAGE gel along with molecular mass markers according
to the method of Laemmli [28]. Some gels were silver
stained, and some were electroblotted onto nitrocellulose
membrane, treated with anti-CF2-R antisera, and devel-
oped as described above.
2.15. Amino acid sequence analysis of CF2-R by
mass spectroscopy (MS)
The electrophoretic bands stained with Coomassie Blue
were excised from the gel with a scalpel and cut into pieces
no larger than 2 mm2. Prior to digestion, the gel pieces
were destained with 50% acetonitrile/50 mM Tris, pH 8.1,
until clear, and then reduced and alkylated with 20 mM
DTT and 40 mM iodoacetamide. In situ enzymatic diges-
tion was performed overnight at 37‡C with modi¢ed se-
quencing grade trypsin (Promega Corporation, Madison,
WI, USA), using 0.01 Wg Wl31 in 20 mM Tris, pH 8.1. The
peptides were extracted from the gel and separated with an
140D capillary HPLC system (Applied Biosystems, Foster
City, CA, USA) running a 300 WmU100 mm Vydac C18
MS 5-Wm column with an acetonitrile gradient in the pres-
ence of 0.1% formic acid and a £ow of 4 Wl min31. The
£ow was directed into a LCQ Deca ion trap mass spec-
trometer (ThermoFinnigan, San Jose, CA, USA). The ion
trap was set to run in data-dependent triple play mode
consisting of full scan (400^1900 amu), zoom scan, fol-
lowed by MS/MS mode. The MS/MS data were correlated
using the SEQUEST search algorithm with tryptic peptide
sequences from the National Center for Biotechnology
Information (NCBI) database and Basic Local Alignment
Search Tool (BLAST) protein search.
2.16. Chemical crosslinking
For a⁄nity crosslinking, the target cells (2U106) were
incubated with [125I]CF2 (15 nM) for 1 h at 37‡C in the
presence or absence of 100-fold excess of unlabeled CF2.
After washing, the cells were suspended in PBS containing
10 mM MgCl2 (pH 8.4), and 25 Wl of crosslinker disucci-
nimidyl suberate (10 mg ml31 suspended in dimethyl sulf-
oxide, Sigma) for 30 min at 4‡C. The reaction was
quenched by using 2.5 ml cold Tris^HCl (pH 7.4) and
1 mM EDTA. The cell suspension was centrifuged, and
the cell pellet was lysed with 50 Wl of lysis bu¡er contain-
ing 2 mM phenyl methyl sulfonyl £uoride, 126 mM Tris^
HCl (pH 7.5), 0.1% Triton X-100 and 10 mM EDTA for
30 min at 4‡C. Lysed cells were centrifuged at 10 000Ug at
4‡C, and the supernatant was fractionated on 12% SDS^
PAGE. The gels were dried using a gel drier (LKB Phar-
macia) and exposed to Konika AX 2355 ¢lm (Konica Co.,
Mahwah, NJ, USA). The ¢lms were developed after ex-
posure of 10^15 days at 370‡C. For detection of CF2-R
in a⁄nity-puri¢ed proteins, the di¡erent fractions of
eluted proteins were applied to the nitrocellulose mem-
brane in a dot-blot apparatus followed by treatment
with [125I]CF2 (12 nM) for 1 h at 37‡C. The membrane
was then washed, and ¢lms were exposed and developed.
3. Results
3.1. Saturation of binding on normal T cells
The saturation of binding of [125I]CF2 to normal mouse
T cells was examined (Fig. 1A). A ¢xed number of cells
(1U106) were incubated with an increasing concentration
of [125I]CF2 (5 pM to 15 nM) in the presence or absence of
100-fold excess of unlabeled CF2. Speci¢c binding was
calculated by subtracting the binding in excess of unla-
beled CF2 (non-speci¢c binding) from the total binding
(binding in the absence of unlabeled CF2). The speci¢c
binding was increased in a dose-dependent manner and
was saturated with 12.0 nM [125I]CF2.
3.2. Scatchard plot analysis of binding of [125I]CF2 to
normal T cells
The data obtained from the speci¢c binding curve were
subjected to Scatchard analysis [22]. The results showed
only one regression line, suggesting the presence of high-
a⁄nity receptors (Fig. 1B). The negative inverse of the
regression coe⁄cient gave a dissociation constant (Kd) of
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1.0309 nM, and the number of receptor sites was 22 000
per T cell.
3.3. Anti-CF2 antisera inhibits the binding of [125I]CF2 to
normal T cells
The speci¢city of the binding of the [125I]CF2 to normal
mouse T cells was investigated using anti-CF2 antisera.
The [125I]CF2 was incubated with either anti-CF2 antisera
or anti-SF antisera as control prior to binding. Anti-CF2
antisera blocked the binding of [125I]CF2 to normal T cells
(80% inhibition), while anti-SF antisera had no signi¢cant
e¡ect (5% inhibition) (Table 1).
3.4. Puri¢cation and detection of CF2-R by immunoa⁄nity
column
Several individual lots of CF2-R were puri¢ed from the
equivalent of 20 mice splenic T cell plasma membranes as
described above. The screening of binding of CF2-R with
CF2 was examined by dot-blot assay at each level of the
plasma membrane puri¢cation steps (data not shown).
The puri¢ed plasma membrane protein (1260 Wg) obtained
by the above method was adsorbed onto a CF2-adsorbed
CNBr-activated Sepharose 4B column. The non-speci¢c
adsorbed protein was ¢rst eluted until the absorbance at
280 nm of the output solution was at the baseline, then
CF2-R was eluted from the column with glycine^HCl bu¡-
er (data not shown). Each fraction was collected, and the
protein concentration of each fraction was detected.
About 15 Wg of the total CF2-R was obtained from the
a⁄nity-puri¢cation method. Screening for CF2-R was
done by directly applying each fraction obtained from
above method onto the nitrocellulose membrane and de-
tecting with anti-CF2 antisera. Fractions eluted with gly-
cine^HCL bu¡er showed the maximum binding, suggest-
ing the presence of a speci¢c receptor for CF2 (data not
shown). No reaction was observed with normal mouse
sera or heterologous anti-SF antisera. The fractions eluted
with Tris bu¡er showed no reactivity with anti-CF2 anti-
sera (data not shown) and thus con¢rmed the presence of
CF2-R in the eluate of glycine^HCl bu¡er. To further
con¢rm the presence of CF2-R, each a⁄nity-puri¢ed frac-
tion was blotted onto nitrocellulose membrane and treated
with [125I]CF2 and only glycine^HCL-eluted fractions
showed the speci¢c binding to [125I]CF2 and, hence, deter-
mined the presence of CF2-R in these fractions (data not
shown).
3.5. Puri¢cation and characterization of CF2-R
Each fraction containing CF2-R was collected and run
on the Shoedex protein column of RP-HPLC using 0.5 M
Tris^HCl (pH 7.4) as the solvent. The proteins were moni-
tored at the 280 nm absorbance range as described above.
Table 1
No antibody Anti-CF2 antibody Anti-SF antibody
Speci¢c bindinga (cpm/1U106 T cells) 2700 ( T 245) 520 ( T 45) 2580 ( T 260)
% Inhibition 0 80 5
a[125I]CF2 was incubated with anti-CF-2 antibody or with anti-SF antibody prior to binding. Speci¢c binding was calculated by incubating T cells
(1U106) with 12 nM [125I]CF2 in the presence or absence of a 100-fold excess of unlabeled CF2. Data represent the mean values of three experiments.
Fig. 1. Speci¢c binding of CF2 to normal mouse T cells. A: Normal
mouse T cells (1U106) were incubated with increasing concentration of
[125I]CF2 in the presence or absence of a 100-fold excess of unlabeled
CF2. Speci¢c binding was calculated by subtraction of non-speci¢c
binding (binding in the presence of unlabeled CF2) from total binding
(in the absence of unlabeled CF2). The results are expressed as the
amount of speci¢cally bound [125I]CF2 (nM)/106 cells. All experiments
were performed in triplicate. B: Equilibrium binding of [125I]CF2 to
T cells was analyzed by the Scatchard method. Each point was calcu-
lated by determining the moles of speci¢cally bound (B) and free (F)
CF2 and plotting them as B/F versus B. The line of best ¢t was con-
structed according to the negative inverse of the regression coe⁄cient.
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The elution pro¢le of CF2-R resolved into a single peak
and further treatment of puri¢ed CF2-R with DTT also
showed a single peak indicating that the CF2-R consists of
a single chain (data not shown). The protein collected
from the RP-HPLC was run on a 12% SDS^PAGE gel
along with molecular mass markers of standard protein,
yielding a single band corresponding to 90^95 kDa (Fig.
2A). The speci¢city of the protein was further con¢rmed
by immunoblotting. Fig. 2B indicates that anti-CF2-R
antisera reacted speci¢cally to the CF2-R and resolved
into a single band. No reaction was observed with normal
mouse sera and anti-SF-R antisera (data not shown).
3.6. Amino acid sequence analysis of CF2-R
The puri¢ed CF2-R was excised from a 12% SDS^
PAGE gel and proteins were digested with trypsin for
overnight. The peptides were separated by capillary
HPLC and run on MS for their sequence analysis as de-
scribed above. The data were correlated using the
SEQUEST from the NCBI database and NCBI^BLAST
protein search. The partial amino acid sequence of CF2-R
was determined (Table 2). The partial amino acid sequence
analysis of CF2-R did not match with the known cyto-
kine, cytokine receptor and other known cytotoxic pro-
teins. It was observed that the sequence is hydrophilic in
nature with serine (S), threonine (T), lysine (K) and argi-
nine (R) on each peptide.
3.7. Chemical crosslinking of CF2 on mouse and
human cells
Crosslinking experiments were performed for the struc-
tural analysis of the CF2-R on di¡erent mouse or human
cells. A major crosslinked product of 100^105 kDa was
seen with normal mouse T cells (Fig. 2C). The ¢nding
indicated that CF2-R on normal mouse T cells has a mo-
lecular mass of 90^95 kDa (after subtracting 10 kDa of
CF2). Crosslinking of radiolabeled CF2 to normal mouse
T cells was completely inhibited if the cells were preincu-
bated in 100-fold excess of unlabeled CF2 (Fig. 2D).
Crosslinking was also performed on the normal mouse
MP and B cells and showed one crosslinked product, while
normal mouse CD4þ and CD8þ cells showed two cross-
linked products (Table 3). The normal human peripheral
blood mononuclear cells and T and B cells were also ex-
amined by crosslinking with [125I]CF2 and showed one
crosslinked product of about the same size as on mouse
T cells (Table 3).
3.8. E¡ect of anti-CF2-R antisera on CF2-induced
cytotoxicity on mouse cells
This experiment was designed to see whether CF2 acts
through its receptor. The target cells were treated with
Table 3
Comparative structural analysis of CF2-R on di¡erent mouse and human cells obtained from chemical crosslinking
Mouse Human
T cells CD4+ CD8+ B cells MP T cells B cells PBMCa
Crosslinked product (kDa) 100^105 30^35 105^110 100^105 100^105 90^105 90^105 90^105
100^110 125^130
[125I]CF2 was added to di¡erent target cells and crosslinked with disuccinimidyl suberate. Cells were lysed, and analyzed by 12% SDS^PAGE followed
by autoradiography. Molecular masses of crosslinked products were determined.
aPBMC: peripheral blood mononuclear cells.
Table 2
Amino acid sequence of CF2-Ra
Peptide 1 I E I S E L N R
Peptide 2 L D S E L K
Peptide 3 L N D L E D A L Q Q A K
Peptide 4 L S L N N Q F A S F I D K
Peptide 5 T L L E G E E S R
Peptide 6 Y E E L Q I T A G R
aCF2-R was excised from SDS^PAGE gel and proteins were digested
with trypsin. The peptides were separated by HPLC and run on MS for
sequence analysis as described in Section 2. Amino acids are shown by
single letters.
116
97
66
45
29
14
A B C D
Fig. 2. Characterization of puri¢ed CF2-R. A: Silver staining of CF2-R
on 12% SDS^PAGE; B: Western immunoblot of CF2-R; CF2-R reac-
tion with anti-CF2-R antisera was visualized with a substrate. Chemical
crosslinking of [125I]CF2 to CF2-R on T cells in the absence (C) or
presence (D) of 100-fold excess unlabeled CF2 as described above. The
left panel shows the molecular mass markers of standard proteins.
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anti-CF2-R antisera (1:100 dilution) for 1 h at 37‡C prior
to treatment with CF2. The data presented in Fig. 3
showed 70^75% inhibition of cytotoxic activity of CF2
on CD4þ and CD8þ cells and total T cells when the cells
were pretreated with anti-CF2-R antisera. Because CF2
cannot kill normal mouse B cells, there is no inhibition
of cytotoxicity on these cells. This suggests that CF2 exerts
its biological e¡ects by binding to its receptor on the cell
surface.
4. Discussion
The ¢ndings in the present study extend our previous
report on the identi¢cation of a receptor for DV-2-induced
CF2 [15]. The results reported herein establish the possi-
bility of the presence of a speci¢c receptor for DV-2-in-
duced CF2 on di¡erent cells. [125I]CF2 bound to CF2-R
present on T cells with high a⁄nity with a Kd of 1.0309
nM, and the number of receptor sites was 22 000 per T cell.
The binding of [125I]CF2 to CF2-R present on normal
T cells is blocked (80% inhibition) only by anti-CF2 anti-
sera, while irrelevant anti-SF antisera have no signi¢cant
e¡ect (5% inhibition) on the binding (Table 1). In our
previous studies we have also identi¢ed the presence of
CF2-R on mouse peritoneal MP, and the CF2-R was sat-
urable with 15 nM [125I]CF2. Scatchard analysis revealed
the presence of intermediate-a⁄nity receptors for CF2 on
peritoneal MP with a dissociation constant of 14.28 nM
and 1.1U106 receptor sites per cell [15]. Scatchard analysis
indicated that interaction of CF2 with its receptor ¢ts with
a bimolecular association of the peptide and a population
of non-interacting receptor sites. This is consistent with
dissociation experiments, which indicate simple ¢rst order
kinetics. Cytokines bind to their receptors with high, low,
and intermediate a⁄nities. The receptor for the tumor
necrosis factor (TNF) [29], granulocyte-MP colony-stimu-
lating factor (GM-CSF) [30] and M-CSF are of only high
a⁄nity [31]. There are high- and low-a⁄nity receptors for
interleukin-5 (IL-5) [31], IL-7 [32], and DV-2-induced SF
[27]. IL-2 has all three ^ high-, low-, and intermediate-
a⁄nity receptors [23]. This study suggests the presence
of high-a⁄nity receptors on murine T cells. Therefore,
T cells were preferred over peritoneal MP for the puri¢ca-
tion of CF2-R.
Solubilization of T cell plasma membrane was per-
formed in the presence of 1% Triton X-100 to replace its
hydrophobic interaction with detergent molecules and to
solubilize the receptor protein from the plasma membrane
in the presence of protease inhibitors. A⁄nity puri¢cation
of receptor proteins usually involves (i) immobilization of
the ligand, (ii) adsorption of a crude, solubilize sample
containing the receptor protein of interest, (iii) elution of
non-speci¢cally adsorbed material by high salt or change
in pH, and (iv) speci¢c elution of the receptor protein
using a low-pH bu¡er. In the present study, CF2 was
immobilized with CNBr-4B beads in a column, and the
puri¢ed T cell plasma membrane was adsorbed on it. Re-
ceptor isolated from a⁄nity chromatography shows sev-
eral 100-fold purity to homogeneity and high binding
speci¢city to its ligand as observed by the above puri¢ca-
tion methods. Inhibitors for TNF-K and TNF-L were also
puri¢ed to homogeneity by a combination of a⁄nity chro-
matography, HPLC, and SDS^PAGE [24]. The receptors
for various cytokines, such as G-CSF [31] and GM-CSF
[30] have been puri¢ed by the above methods and each is
composed of single bands. RP-HPLC achieved puri¢ca-
tion of CF2-R in a single sharp peak, and SDS^PAGE
determined the CF2-R molecular mass corresponding to
90^95 kDa. IL-2R eluted by RP-HPLC gave a single peak
and a single band [23], DV-2-induced SF-R split into two
peaks by RP-HPLC [27], and IL-1 receptor antagonist
(IL-1Ra) gave three species of native IL-1Ra by RP-
HPLC [33].
With the above analysis, it was di⁄cult to distinguish
between physiological and artifactual binding and whether
one or more proteins are associated with an individual
receptor. To resolve such ambiguities, chemical crosslink-
ing was studied by homobifunctional crosslinking reagent
disuccinimidyl suberate, which covalently couples adjacent
amino groups. This reagent has been used extensively to
identify the cellular receptors for a number of cytokines
such as TNF [29], T cell growth factor [34], and IL-5 [35].
The ¢nding presented here showed the presence of a 100^
105-kDa crosslinked product, and the binding was com-
pletely inhibited with preincubation of 100-fold excess of
unlabeled CF2. These data support the implication that
CF2-R could be the receptor for CF2. The binding of
CF2 to CF2-R was speci¢c and is supported as follows:
(i) by ¢nding a marked inhibition of binding by pretreat-
ment with anti-CF2 antisera but not by heterologous anti-
sera; (ii) by ¢nding that puri¢ed CF2-R (a⁄nity and RP-
HPLC) reacted only with anti-CF2-R antisera but not
with heterologous (anti-SF and anti-SF-R) antisera or
normal mouse antisera; (iii) by crosslinking of [125I]CF2
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Fig. 3. E¡ect of anti-CF2-R antisera on CF2-induced cytotoxicity. Tar-
get cells (1U106) were pretreated with anti-CF2-R antisera followed by
treatment with CF2 as described above. The bars represent the standard
deviation of three individual experiments.
FEMSIM 1561 24-7-03
P.D. Khare et al. / FEMS Immunology and Medical Microbiology 38 (2003) 35^43 41
on murine T cells, and ¢nding that this speci¢c binding
was signi¢cantly inhibited by excess of unlabeled CF2
(Fig. 2C,D); and (iv) by ¢nding that pretreatment of tar-
get cells with anti-CF2-R antisera signi¢cantly inhibited
CF2-induced cytotoxicity (Fig. 3). This study also suggests
the active role of CF2-R in CF2-induced cell death mech-
anism at least in vitro, and its possible role in vivo. These
¢ndings were similar to that for anti-TNF-K antibodies,
which inhibited the cytotoxic e¡ect of TNF-K [29]. The
partial amino acid sequences of CF and CF2 have no
homology to other known cytokines. The analysis of the
partial amino acid sequence of CF2-R suggests that CF2-
R has no homology with other known cytokine, cytokine
receptor and cytotoxic protein families, which suggests
that CF2-R could be a novel receptor protein.
The previous study revealed that CF2-induced DHF-
like symptoms in mice [10,11], and recent progress in cy-
tokine research has provided new insight into the patho-
genesis of DHF [36^38]. The high levels of soluble IL-2R,
soluble CD4 and CD8 [37], and IL-1Ra [38] were detected
in DHF patients, indicating a progressive and important
role of cytokines and their receptors in the immunopatho-
genesis of DHF. The characterization of the CF2-R is of
interest not only because it elucidates a new aspect of CF2
biology, but also because it may broaden the understand-
ing of CF2-induced immunopathological lesions in mice.
The presence of CF2-R on normal human cells may sug-
gest a new role of CF2 and CF2-R in the pathogenesis of
DHF and may provide an important approach in the
treatment and prevention of DHF. The DHF-like patho-
logical lesions produced by mCF in mice can be prevented
by active vaccination of mice using mCF as an antigen.
The immunized mice were protected, which resulted in the
absence of clinical symptoms of the disease against a sub-
sequent challenge with mCF as well as with a lethal i.c.
dose of DV-2 [39]. These studies suggest a vaccine strategy
that should be directed against the primary cause of the
disease (the cytokine) rather than the infective agent [39].
The present study also indicates the need to look for ex-
pression of CF2 and its possible receptor CF2-R in such
cases.
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